GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » Total Equity

CATX (Perspective Therapeutics) Total Equity : $290.67 Mil (As of Dec. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics Total Equity?

Perspective Therapeutics's total equity for the quarter that ended in Dec. 2024 was $290.67 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.


Perspective Therapeutics Total Equity Historical Data

The historical data trend for Perspective Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perspective Therapeutics Total Equity Chart

Perspective Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.72 67.41 61.28 75.18 290.67

Perspective Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.18 229.89 341.00 328.47 290.67

Perspective Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Perspective Therapeutics's Total Equity for the fiscal year that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=341.101-50.433
=290.67

Perspective Therapeutics's Total Equity for the quarter that ended in Dec. 2024 is calculated as

Total Equity=Total Assets(Q: Dec. 2024 )-Total Liabilities(Q: Dec. 2024 )
=341.101-50.433
=290.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perspective Therapeutics Total Equity Related Terms

Thank you for viewing the detailed overview of Perspective Therapeutics's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Perspective Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
Executives
Heidi Henson director 2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Johan M. Spoor director, officer: CEO 500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Jonathan Robert Hunt officer: Chief Financial Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Williamson Robert F Iii director 140 LASALLE AVENUE, PIEDMONT CA 94610
Lori A Woods officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Markus Puhlmann officer: Chief Medical Officer 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Frank Morich director 40 GUEST STREET, BOSTON MA 02135
Mark John Austin officer: Controller/Prin Fin&Acct Offic 350 HILLS ST, STE 106, RICHLAND WA 99354
Alan Hoffmann director 3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Michael W Mccormick director 9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh officer: Vice President 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Philip J Vitale director 8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Michael Krachon officer: VP of Sales & Marketing 350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Krista Cline officer: Dir. of Operations, Secretary 350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter officer: VP of Human Resources 350 HILLS STREET SUITE 106, RICHLAND WA 99354